VA Palo Alto HSC / Stanford School of Medicine
Welcome,         Profile    Billing    Logout  
 31 Trials 
17 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Stern, Yaakov
NCT01222351: Measuring Brain Amyloid Plaque Load in Older Adults Using BAY 94-9172

Completed
N/A
161
US
BAY 94-9172 (Florbetaben), Florbetaben, Bay 91-9172
New York State Psychiatric Institute, Bayer, National Institute on Aging (NIA)
Late Onset Alzheimer Disease
10/14
10/14
Graff-Radford, Neill R
START, NCT05531656: A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Recruiting
2
540
US
CT1812, Study Drug Active, Placebo, Matching Placebo
Cognition Therapeutics, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium
Early Alzheimer's Disease
04/27
04/27
Smith, Amanda
REFOCUS-ALZ, NCT05026177: Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

Terminated
3
1125
Canada, US, RoW
Simufilam, PTI-125, Placebo
Cassava Sciences, Inc., Premier Research Group plc
Alzheimer Disease
12/24
12/24
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
Spectra, NCT05393284: Phase 2 Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy

Active, not recruiting
2
114
US
OPL-0401 Dose 1, Placebo
Valo Health, Inc.
Non-proliferative Diabetic Retinopathy, Proliferative Diabetic Retinopathy
08/24
08/24
MAGIC, NCT05681884: Safety and Efficacy of Faricimab in Patients With NPDR

Active, not recruiting
2
179
US
Faricimab
Greater Houston Retina Research, Genentech, Inc.
Non-Proliferative Diabetic Retinopathy
03/26
04/26
NCT05715346: LEV102 Topical Gel in Acquired Blepharoptosis

Completed
1/2
33
US
LEV102 1.0%, LEV102 2.0%, Vehicle
Levation Pharma, Ltd.
Acquired Blepharoptosis
06/23
06/23
i-GAIN, NCT05797896: Investigating Geographic Atrophy Insights () Natural History Study

Recruiting
N/A
250
Europe, US
Complement Therapeutics
Dry Age-related Macular Degeneration, Geographic Atrophy, Retinal Disease, Macular Degeneration, Macular Atrophy, Retinal Degeneration, Eye Diseases
12/26
12/26
Obisesan, Thomas O
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
NCT05122598: Development and Evaluation of Computerized Olfactory Training Program for Cognitive Decline in Early Alzheimer's Disease

Recruiting
2
200
US
COT, COT with olfactory stimulants, Sham, Sham COT
Evon Medics LLC, Howard University, Family and Medical Counseling Service, Inc, Medical Home Development Group, National Institute on Aging (NIA), Johns Hopkins University
Mild Cognitive Impairment, Early Alzheimer's Disease, Memory Impairment
04/23
04/23
START, NCT05531656: A Study to Evaluate the Safety and Efficacy of CT1812 in Early Alzheimer's Disease

Recruiting
2
540
US
CT1812, Study Drug Active, Placebo, Matching Placebo
Cognition Therapeutics, National Institute on Aging (NIA), Alzheimer's Clinical Trials Consortium
Early Alzheimer's Disease
04/27
04/27
Marshall, Gad
NCT06489548: Assessment of Foralumab Safety and Modulation of Microglial Activation in Alzheimer's Disease

Not yet recruiting
2
16
US
Foralumab TZLS-401 50 µg, Foralumab TZLS-401 100 µg
Brigham and Women's Hospital, Tiziana Life Sciences LTD
Dementia, Alzheimers Disease, Mild Cognitive Impairment Due to Alzheimer's Disease
06/26
12/26
Sadowski, Martin
ENVISION, NCT05310071 / 2022-001671-14: A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

Terminated
3
1027
Europe, Canada, Japan, US, RoW
Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo
Biogen, Biogen Idec Research Limited
Alzheimer's Disease
08/24
08/24
NEUP11-7, NCT05267535: Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease

Active, not recruiting
2/3
225
Canada, US
Piromelatine 20 mg, Neu-P11, Placebo
Neurim Pharmaceuticals Ltd., Syneos Health
Alzheimer's Disease
06/25
06/25
NCT04784416: Transcranial Photobiomodulation for Alzheimer's Disease (TRAP-AD)

Recruiting
2
125
US
Active tPBM-2.0, Sham tPBM-2.0, 18F-MK-6240
NYU Langone Health, National Institutes of Health (NIH), Alzheimer's Association, LiteCure LLC
Mild Cognitive Impairment, Alzheimer Disease
10/25
01/26
PROGRESS-AD, NCT06079190: Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease

Recruiting
2
282
Europe, Canada, US, RoW
GSK4527226, Placebo
GlaxoSmithKline, Alector Inc.
Alzheimer's Disease
12/26
02/29
CELIA, NCT05399888: A Study to Learn About the Safety of BIIB080 Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age

Active, not recruiting
2
416
Europe, Canada, Japan, US, RoW
BIIB080, ISIS 814907, BIIB080-matching placebo
Biogen
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
05/26
01/29
Wint, Dylan
No trials found
Chao, Steven
No trials found

Download Options